Experimental evidence suggest that FFAR-targeted therapies offer the potential to reduce hyperglycemia without inducing hypoglycemia, promote insulin sensitivity, reduce obesity, and prevent hepatic lipotoxicity. Here, INS is linked to obesity disorder.